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Introduction
Ethical concerns about medical ghost-
writing have been directed primarily at
‘‘guest’’ authors and the pharmaceutical
companies that pay them. One voice that
is largely missing is that of the ghostwriters
themselves who, after all, create the
documents that are in the ethical and
legal crosshairs. Without them, one could
argue, there can be no fraud, because it is
they who create the fraudulent product.
For almost 11 years, I worked as a
medical writer, creating a variety of pieces
including the occasional ghostwritten arti-
cle. For the most part, I never saw the
finished paper, nor did I care to. This
article describes what I did, why I did it,
why I stopped doing it, and what I think
might be done about the problem of fraud
in authorship.
What I Did
In line with the description on the
American Medical Writers’ Association
Web site about what medical writers do
[1], I wrote slide kits, monographs,
executive summaries, journal articles,
backgrounders, newsletters, competitive
analyses, publication plans, video scripts,
audio scripts, and continuing medical
education (CME) programs for physicians
and nurses. Each piece (‘‘job’’, in adver-
tisingspeak) was born out of the publica-
tions planning strategy developed for a fee
by the medical education (meded) compa-
ny for the pharmaceutical corporation.
Medical writers are highly deadline-
driven. For one hormone patch product I
worked on, writers and ‘‘creatives’’ were
asked to remain at work until close to
midnight to await results from physician
focus groups on the West Coast. After
receiving the client’s (i.e., pharma’s) take
on the focus group results for that day, we
rewrote the messages for the next day’s
groups and sent them to the West Coast. A
slide rose or fell on subtleties: in one slide
kit draft in my files, an account executive
added ‘‘Importance of early intervention’’
to a slide titled ‘‘Chronic Pain.’’ The bullet
does not help define chronic pain, but it
plants the idea that treatment should be
started ASAP in the mind of the listener.
Clients admonished us to always distin-
guish between ‘‘adverse effects’’ (for com-
petitors’ products: Drug X could have
caused the heart attack) and adverse events
(our product: some patients taking Drug X
just happened to have a heart attack).
Ghostwriting was a small, but real, part
of my duties. I have seen published pieces
that are virtually identical to the final drafts
I submitted. Regardless of what I wrote,
though, for many years I considered my
role to be similar to that of a highly paid
technician and did not question its ethics.
Why I Did It
My background may not have been
typical for a medical writer, but neither
was it uncommon. I enjoyed a research
career up to the point where I no longer
enjoyed it, which came a few years after
receiving my PhD. Several things about an
academic career did not encourage me to
continue, although I loved research and
working in the lab. These included the
difficulty of getting tenure and the possi-
bility of finding myself unemployed in my
mid-40s: there were 12 newly hired
assistant professors in the department
where I did my second postdoc, with an
average time to tenure of more than 10
years.
Ironically, though, it was the ethics of
authorship that sent me fleeing academia.
I ran afoul of a colleague in my last
research position, who assumed that
postdocs would draft his grant renewal
application. I commented offhandedly one
day, ‘‘Well, I for one would never write
something and have someone else sign his
name to it—that would be unethical.’’ Dr.
X told me that that was when he realized
that it would not work out for me to
continue there, as my attitude was unac-
ceptably insubordinate. Faced with the
need for a job, I resigned and answered an
ad in The New York Times for a company
that needed medical writers. This began a
series of freelance and in-house jobs with a
range of medical communications compa-
nies.
I believe that many of the factors that
kept me in medical writing apply to most
medical writers. First, I believed that I was
helping people: sick people need drugs,
and physicians need to know about those
drugs to prescribe them appropriately.
Second, I had young children and valued
the flexibility of working at home, which
most meded companies offered at least
part of the time. Third, the work was
interesting: I interacted with top research-
ers and was assured of an ease of access
that I never would have had as an assistant
professor. Fourth, the money was good.
Really good, especially compared with the
typical assistant professor salary. And
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run—it was fun. Traveling, eating in
high-end restaurants, wearing fashionable
clothes, and rushing to meet important
deadlines—what’s not to like?
Why I Stopped Doing It
It turned out, there was quite a bit not
to like. I’d started in smaller companies
headed by PhDs or MD/PhDs who dealt
directly with the primary researchers and
the pharmaceutical companies. There
were no advertising types in sight, and I
had frequent, direct communication with
the physician-authors. I saw my role as
helping a busy researcher write up re-
search results: he or she did the research
(which I’d already decided I didn’t want to
do), and I got to analyze and describe it.
But as my career developed, several of
these smaller firms went out of business, and
I began to get more work from larger meded
companies that were part of large advertis-
ing agencies. The bigger the agency, the
more likely it was that my contact person
was someone without a science background.
In the worst of these settings, I discussed
projects onlywiththe programmanager and
had limited—or no—access to the ‘‘author.’’
The work itself began to lose its charm.
My preferred area of interest was oncol-
ogy, and the lighter-weight assignments
that increasingly came my way were not as
interesting. It was hard to muster up much
enthusiasm for the importance of treating,
say, subclinical hypothyroidism—indeed,
subclinical anything. In addition, the ethical
issues began to tap me on the shoulder:
perhaps the most memorable example of
this was a contraceptive product that
caused severe, unpredictable vaginal
bleeding in some women. My job was to
draft a monograph that would profile the
product’s benefits, one of which, according
to the client, was that although the
bleeding could be severe, it was at least
something that women could anticipate.I n
other words—the bad news is that a
meteorite will strike you, but the good
news is—a meteorite will strike you!
This kind of doublespeak became more
and more troubling, and my career came to
an end over a job involving revising a
manuscript supporting the use of a drug for
attention deficit-hyperactivity disorder
(ADHD), with a duration of action that fell
between that of shorter- and longer-acting
formulations. However, I have two children
with ADHD, and Ifailed to seethebenefit of
a drug that would wear off right at
suppertime, rather than a few hours before
or a few hours after. Suppertime is a time in
ADHD households when tempers and
homework arguments are often at their
worst. So I questioned the account executive
at the large agency that had hired me. In
particular, I wanted to ask the physician
author their view of the drug’s benefits.
Attempts to discuss my misgivings with the
mededcontactmetwiththecurtadmonition
to ‘‘just write it.’’ But perhaps because this
particular disorder was so close to home, I
was unwilling to turn this ugly duckling of a
‘‘me-too’’ drug into a marketable swan.
I decided it was time to burn my medical
writing bridges and contacted The New York
Times, which coincidentally had planned an
investigative article on pharmaceutical
marketing to physicians. I was interviewed
for this article, written by Melody Petersen,
by Ms. Petersen and Walt Bogdanich [2].
Shortly after its publication (November 22,
2002; page A1), I received a polite letter
from an executive of the meded company
asking for all the materials back and
reminding me of my confidentiality agree-
ment. I also received a direct threat of legal
retaliation in a phone call from my former
contact at that agency.
What I Think Now
Wordsmithing is ubiquitous in all pro-
motional writing, not just ghostwriting: it’s
the name of the game. Yet advertising
masquerading as unbiased health infor-
mation clearly threatens the fundamental
assumptions of scientific research. Can
pharma, clinicians, researchers, and con-
sumer protection advocates work together
without distortion?
I believe that they can. A system could
be put in place that fortuitously addresses
another critical problem—the underem-
ployment of medical writers, who, possess-
ing academic training and experience
without opportunities to use them, are
‘‘all dressed up’’ intellectually with no
place to go. All too often, people like me
find themselves unemployed or in science-
related positions such as teaching that
offer little hope of advancement in a job
market that has not added new jobs in
biomedicine in 20 years despite a doubling
in the number of PhDs in that field [3].
If research centers that employ people
who serve as ‘‘guest authors’’ (often the
same places that accredit CME programs
funded by pharmaceutical money) were, in
addition, to employ medical writers, much
could be accomplished toward cleaning up
the ethics of authorship. Funds to pay
medical writers and editors could be given
to these centers by pharmaceutical com-
panies, allowing the writers to work
directly with researchers. The pharmaceu-
tical company’s role would be limited to
factchecking the document and clarifying
issues about dosage, adverse events, post-
marketing developments, etc., and the
final product would be submitted for peer
review by the researcher personally. The
incentive for the pharmaceutical company
would be to educate and inform physicians
and researchers, pure and simple. Drug
promotion would still occur, but would be
in the hands of advertising agencies.
This approach would eliminate the
meded companies, currently ‘‘the middle-
man’’ between pharma and physician. It
would reduce the need for journals to take
on the entire responsibility of vetting
submitted manuscripts for conflicts of
interest related to authorship, because the
academic institution that employed the
researcher-author would have a stake in
ensuring the paper’s accuracy as well as in
exposing conflicts of interest. The increased
visibility to the research community of the
pharmaceutical company could reduce the
likelihood of unfounded claims or egregious
promotion of off-label use. This arrange-
ment could shorten the interval between
research and publication,andensurea high
quality of publications. Finally, one other
stakeholder would surely be well pleased by
such an arrangement—the medical writer,
who would be glad to once again work in
an academic environment.
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